Matches in SemOpenAlex for { <https://semopenalex.org/work/W3176403805> ?p ?o ?g. }
- W3176403805 endingPage "1072" @default.
- W3176403805 startingPage "1065" @default.
- W3176403805 abstract "Background: In the SOLOIST-WHF (Effect of Sotagliflozin on Cardiovascular Events in Patients With Type 2 Diabetes Post Worsening Heart Failure) trial, sotagliflozin, a sodium–glucose cotransporter-1 and sodium–glucose cotransporter-2 inhibitor, reduced total occurrences of cardiovascular deaths, hospitalizations for heart failure, and urgent visits for heart failure relative to placebo by 33%. Objective: To determine whether sotagliflozin increased the prespecified efficacy outcome of days alive and out of the hospital (DAOH) in the SOLOIST-WHF trial. Design: Randomized, double-blind, placebo-controlled trial. (ClinicalTrials.gov: NCT03521934) Setting: 306 sites in 32 countries. Participants: 1222 patients with type 2 diabetes and reduced or preserved ejection fraction who were recently hospitalized for worsening heart failure. Intervention: 200 mg of sotagliflozin once daily (with a possible dose increase to 400 mg) or matching placebo. Measurements: The primary analysis included hospitalizations for any reason on the basis of investigator-reported incidence and duration of admissions after randomization. Days alive and out of the hospital and its converse (days dead and days in the hospital) were analyzed using prespecified Poisson regression models. Results: Although similar proportions of patients in the sotagliflozin and placebo groups were hospitalized at least once (38.5% vs. 41.4%), fewer patients in the sotagliflozin group were hospitalized more than once (16.3% vs. 22.1%). There were 64 and 76 deaths in the sotagliflozin and placebo groups, respectively. The DAOH rate in the sotagliflozin group was 3% higher than in the placebo group (rate ratio [RR], 1.03 [95% CI, 1.00 to 1.06]; P = 0.027). This difference was primarily driven by a reduction in the rate of days dead (RR, 0.71 [CI, 0.52 to 0.99]; P = 0.041) rather than by a reduction in the rate of days hospitalized for any cause. For every 100 days of follow-up, patients in the sotagliflozin group were alive and out of the hospital for 3% or 2.9 more days than those in the placebo group (91.8 vs. 88.9 days); this difference reflected a 2.6-day difference in days dead (6.3 vs. 8.9 days) and a 0.3-day difference in days in the hospital (1.9 vs. 2.2 days). Limitation: Other than heart failure, the primary reason for each hospitalization was unspecified. Conclusion: Sotagliflozin increased DAOH, a metric that may provide an additional patient-centered outcome to capture the totality of disease burden. Future studies are needed to quantify the consequences of increasing DAOH in terms of health economics and patient quality of life. Primary Funding Source: Sanofi at initiation and Lexicon Pharmaceuticals at completion." @default.
- W3176403805 created "2021-07-05" @default.
- W3176403805 creator A5002776609 @default.
- W3176403805 creator A5003464831 @default.
- W3176403805 creator A5006527198 @default.
- W3176403805 creator A5009162758 @default.
- W3176403805 creator A5010571732 @default.
- W3176403805 creator A5012209049 @default.
- W3176403805 creator A5017272571 @default.
- W3176403805 creator A5017349008 @default.
- W3176403805 creator A5023587190 @default.
- W3176403805 creator A5026602252 @default.
- W3176403805 creator A5050005771 @default.
- W3176403805 creator A5053760015 @default.
- W3176403805 creator A5055175064 @default.
- W3176403805 creator A5055479743 @default.
- W3176403805 creator A5067237537 @default.
- W3176403805 creator A5067972379 @default.
- W3176403805 creator A5071945904 @default.
- W3176403805 creator A5072470914 @default.
- W3176403805 creator A5074566771 @default.
- W3176403805 creator A5078418468 @default.
- W3176403805 creator A5080334509 @default.
- W3176403805 creator A5080414941 @default.
- W3176403805 creator A5086589108 @default.
- W3176403805 date "2021-08-01" @default.
- W3176403805 modified "2023-10-05" @default.
- W3176403805 title "Effect of Sotagliflozin on Total Hospitalizations in Patients With Type 2 Diabetes and Worsening Heart Failure" @default.
- W3176403805 cites W1964313277 @default.
- W3176403805 cites W2069874953 @default.
- W3176403805 cites W2098148402 @default.
- W3176403805 cites W2121046269 @default.
- W3176403805 cites W2146264128 @default.
- W3176403805 cites W2412117889 @default.
- W3176403805 cites W2510990897 @default.
- W3176403805 cites W2626446274 @default.
- W3176403805 cites W2899764361 @default.
- W3176403805 cites W2900413769 @default.
- W3176403805 cites W2903198138 @default.
- W3176403805 cites W2911404131 @default.
- W3176403805 cites W2974260792 @default.
- W3176403805 cites W2988829342 @default.
- W3176403805 cites W3020792715 @default.
- W3176403805 cites W3029305504 @default.
- W3176403805 cites W3081830235 @default.
- W3176403805 cites W3089283105 @default.
- W3176403805 cites W3092379111 @default.
- W3176403805 cites W3100542962 @default.
- W3176403805 cites W3101044784 @default.
- W3176403805 cites W3101690455 @default.
- W3176403805 cites W3122900688 @default.
- W3176403805 doi "https://doi.org/10.7326/m21-0651" @default.
- W3176403805 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34152828" @default.
- W3176403805 hasPublicationYear "2021" @default.
- W3176403805 type Work @default.
- W3176403805 sameAs 3176403805 @default.
- W3176403805 citedByCount "27" @default.
- W3176403805 countsByYear W31764038052021 @default.
- W3176403805 countsByYear W31764038052022 @default.
- W3176403805 countsByYear W31764038052023 @default.
- W3176403805 crossrefType "journal-article" @default.
- W3176403805 hasAuthorship W3176403805A5002776609 @default.
- W3176403805 hasAuthorship W3176403805A5003464831 @default.
- W3176403805 hasAuthorship W3176403805A5006527198 @default.
- W3176403805 hasAuthorship W3176403805A5009162758 @default.
- W3176403805 hasAuthorship W3176403805A5010571732 @default.
- W3176403805 hasAuthorship W3176403805A5012209049 @default.
- W3176403805 hasAuthorship W3176403805A5017272571 @default.
- W3176403805 hasAuthorship W3176403805A5017349008 @default.
- W3176403805 hasAuthorship W3176403805A5023587190 @default.
- W3176403805 hasAuthorship W3176403805A5026602252 @default.
- W3176403805 hasAuthorship W3176403805A5050005771 @default.
- W3176403805 hasAuthorship W3176403805A5053760015 @default.
- W3176403805 hasAuthorship W3176403805A5055175064 @default.
- W3176403805 hasAuthorship W3176403805A5055479743 @default.
- W3176403805 hasAuthorship W3176403805A5067237537 @default.
- W3176403805 hasAuthorship W3176403805A5067972379 @default.
- W3176403805 hasAuthorship W3176403805A5071945904 @default.
- W3176403805 hasAuthorship W3176403805A5072470914 @default.
- W3176403805 hasAuthorship W3176403805A5074566771 @default.
- W3176403805 hasAuthorship W3176403805A5078418468 @default.
- W3176403805 hasAuthorship W3176403805A5080334509 @default.
- W3176403805 hasAuthorship W3176403805A5080414941 @default.
- W3176403805 hasAuthorship W3176403805A5086589108 @default.
- W3176403805 hasBestOaLocation W31764038052 @default.
- W3176403805 hasConcept C126322002 @default.
- W3176403805 hasConcept C134018914 @default.
- W3176403805 hasConcept C141071460 @default.
- W3176403805 hasConcept C142724271 @default.
- W3176403805 hasConcept C168563851 @default.
- W3176403805 hasConcept C204243189 @default.
- W3176403805 hasConcept C204787440 @default.
- W3176403805 hasConcept C27081682 @default.
- W3176403805 hasConcept C2778198053 @default.
- W3176403805 hasConcept C535046627 @default.
- W3176403805 hasConcept C555293320 @default.
- W3176403805 hasConcept C71924100 @default.
- W3176403805 hasConceptScore W3176403805C126322002 @default.